It is believed that a defective ANP-BNP/NPRA signaling might promote a maladaptive metabolic disorders, which could trigger lipid accumulation, decreased mitochondrial function, hyperglycemia, and insulin resistance leading to hypertension and CVDs in humans. Here, NPPA is linked to hypertensive disorder.